Acute promyelocytic leukemia: recent advances in therapy and molecular basis of response to arsenic therapies.
about
Selective leukemic-cell killing by a novel functional class of thalidomide analogsThe biphasic redox sensing of SENP3 accounts for the HIF-1 transcriptional activity shift by oxidative stressChromosomal translocations involving the MLL gene: molecular mechanisms.Targeting catalase but not peroxiredoxins enhances arsenic trioxide-induced apoptosis in K562 cells.Causes of oncogenic chromosomal translocation.Arsenic suppresses gene expression in promyelocytic leukemia cells partly through Sp1 oxidation.c-Met inhibitor synergizes with tumor necrosis factor-related apoptosis-induced ligand to induce papillary thyroid carcinoma cell deathSilymarin protects plasma membrane and acrosome integrity in sperm treated with sodium arseniteSalvianolic Acid B prevents arsenic trioxide-induced cardiotoxicity in vivo and enhances its anticancer activity in vitro.Arsenic-based antineoplastic drugs and their mechanisms of action.Targeted therapy in leukemia.Mineral arsenicals in traditional medicines: orpiment, realgar, and arsenolite.Flex-Hets differentially induce apoptosis in cancer over normal cells by directly targeting mitochondria.Acute promyelocytic leukemia: what are the treatment options?Role of ursolic acid chalcone, a synthetic analogue of ursolic acid, in inhibiting the properties of CD133(+) sphere-forming cells in liver stem cells.Preparation, characterization, in vivo and in vitro studies of arsenic trioxide Mg-Fe ferrite magnetic nanoparticles.How plausible is the use of dietary n-3 PUFA in the adjuvant therapy of cancer?Andrographolide inhibits growth of acute promyelocytic leukaemia cells by inducing retinoic acid receptor-independent cell differentiation and apoptosis.Anion exchanger 2 mediates the action of arsenic trioxide.Suppression of p53 and p21CIP1/WAF1 reduces arsenite-induced aneuploidy.Arsenic in leukemia: a RSKy businessTargeting Hsp90 by 17-AAG in leukemia cells: mechanisms for synergistic and antagonistic drug combinations with arsenic trioxide and Ara-C.Inhibition of E2F1 activity and cell cycle progression by arsenic via retinoblastoma protein.
P2860
Q30479632-E3BC260D-AB7A-46FF-A79E-BC84DE498D64Q33570846-FCF72E13-28DC-49B8-B9B6-54E1A93FD59BQ35128590-D864E585-F7DC-451C-BA48-1FC807CD7904Q35223411-72968E70-483B-49E4-A799-77F1A772823EQ35570942-50B892CB-A277-430C-B59A-7F6ED9F3FC37Q35847861-4488C099-250D-452C-8F01-69A135452BA3Q35872516-7126CABC-704B-41D7-897B-BD81DB26D4D6Q36007574-7DC0BCA3-2B97-499F-A57E-D6D4AD139955Q36801861-57FB1375-A3AC-4797-821B-A8CDD2BB9BCAQ37145891-0DB379CD-F02F-450C-A39D-60238CBE36B6Q37147758-D0531750-4FF0-4467-A365-C62B1CD8D4ECQ37221305-DB81E058-83C5-45F2-8C79-ACB498151442Q37239235-50B84456-A9EE-4647-A518-365B1993BD20Q37693929-812E558A-42D6-49AD-B7C9-D4C5B4BF49D8Q38875128-F09AD090-EB30-4505-B0D5-9FEF014AFAF6Q39147156-3BB85DAB-0D1C-441B-80F8-04C603AE01CCQ39771420-483A2380-9D3F-4B8A-B357-93232BD0F075Q39898245-47ED68E0-6B35-41C9-924A-3493901E9128Q40224250-D7372441-6975-4627-9F64-6280D9AB5316Q41893597-C082E682-9B9E-462D-AA9E-AE4953B87824Q41960709-8DBF5551-72BD-4B19-BAD0-B480F8D6F2D3Q46947497-A20019D6-0B59-42F0-9E16-E11F02BCF7B9Q47842837-79867F9C-7655-40D3-82DB-25AB53F17796
P2860
Acute promyelocytic leukemia: recent advances in therapy and molecular basis of response to arsenic therapies.
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
2005年论文
@zh
2005年论文
@zh-cn
name
Acute promyelocytic leukemia: ...... response to arsenic therapies.
@ast
Acute promyelocytic leukemia: ...... response to arsenic therapies.
@en
type
label
Acute promyelocytic leukemia: ...... response to arsenic therapies.
@ast
Acute promyelocytic leukemia: ...... response to arsenic therapies.
@en
prefLabel
Acute promyelocytic leukemia: ...... response to arsenic therapies.
@ast
Acute promyelocytic leukemia: ...... response to arsenic therapies.
@en
P1476
Acute promyelocytic leukemia: ...... response to arsenic therapies
@en
P2093
Chi V Dang
Wen-Chien Chou
P356
10.1097/01.MOH.0000148552.93303.45
P577
2005-01-01T00:00:00Z